Product Images Praluent
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 35 images provide visual information about the product associated with Praluent NDC 72733-5901 by Sanofi Us Corporation, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Figure 1 - s praluent 01
Figure 2 - s praluent 02
The text describes a graph that shows the percent change of LDL-C (a type of cholesterol) from baseline over time (weeks). There were two groups in the study, one that received a drug called PRALUENT and a placebo group. The text also shows the sample size of each group at different time points.*
Figure 3 - s praluent 03
This is a graph representing the mean percent change in LDL-C from baseline for patients on Praluent and Placebo over 52 weeks. The time points are labeled from 4 to 52 weeks and the data is represented by a line graph with the x-axis being the weeks and the y-axis showing the percentage change in LDL-C levels. The data shows that Praluent had a greater impact on reducing LDL-C levels compared to Placebo.*
s praluent 03a
This is a graph depicting the calculated percentages of change in LDL cholesterol levels from baseline over a period of 12 weeks. The graph includes data from three groups: a placebo group consisting of 157 individuals, a Praluent75 Q2W group consisting of 78 individuals, and a Praluent 300 Q4W group consisting of 312 individuals. The X-axis indicates the time points measured in weeks, while the Y-axis shows the percentage change in LDL cholesterol levels.*
s praluent 03b
Figure - s praluent 04
Figure - s praluent 05
Figure - s praluent 06
Figure - s praluent 07
Figure - s praluent 08
Picture A - s praluent 09
Figure B - s praluent 10
Figure - s praluent 11
Figure - s praluent 12
Figure - s praluent 13
Figure - s praluent 14
Figure - s praluent 15
Figure - s praluent 16
Figure - s praluent 17
Figure - s praluent 18
Figure - s praluent 19
Figure - s praluent 20
Figure - s praluent 21
Figure - s praluent 22
Picture A - s praluent 23
Figure B - s praluent 24
The text is not available as it contains only few characters that do not make any sense.*
Figure - s praluent 25
Figure - s praluent 26
Figure - s praluent 27
This is a command prompting someone to release a button they may be holding down or pressing. The instruction is to release the button without delay.*
Figure - s praluent 28
Figure - s praluent 29
Figure - s praluent 30
Figure - s praluent 31
Figure - s praluent 32
This is a description of Praluent® medication for subcutaneous injection. It comes in a carton that contains two single-dose pre-filled pens, along with the package insert, patient information, and instructions for use. Each pen contains 75 mg of alirocumab, histidine (8 mM), polysorbate 20 (0.1 mg), sucrose (100 mg), and Water for Injection. The medication is manufactured by sanofi=aventis US. LLC and stored in a refrigerator at 36°F to 46°F (2°C to 8°C) in the original carton to protect from light. It should not be used if the seal is broken or the package is damaged. Once removed from the refrigerator, it must be used within 30 days or discarded. If needed, patients/caregivers may store PRALUENT® at room temperature up to 77°F (25°C) for a maximum of 30 days in the original carton to protect from light. The dosage and administration details are available in the package insert.*
Figure - s praluent 33
Praluent® (alirocumab) is a subcutaneous injection used to treat high cholesterol. It comes in pre-filled pens that contain 150 mg/mL of the medication. Each single-dose pre-filled pen contains 150 mg alirocumab, polysorbate 20, sucrose, and Water for Injection. Patients should follow the instructions given in the package insert for dosage and administration. The drug should be stored in a refrigerator and it is not to be used after the expiration date. The medicine should be used within 30 days of being removed from the refrigerator or it should be discarded. Patients can store Praluent® at room temperature in the original carton for a maximum of 30 days. The drug’s potency has no US standard. Praluent® must be kept out of reach of children and should not be used if the seal on the package is broken.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.